August 2013
Reactions Weekly;8/24/2013, Issue 1466, p13
An abstract of the article "Long-term therapeutic efficacy of cetuximab in treating metastatic colorectal cancer following failure of previous chemotherapy with FOLFOX4 and FOLFIRI," by P. Beneš ans colleagues is presented.


Related Articles

  • PD-0028FIRST-LINE CETUXIMAB WITH FOLFOX OR FOLFIRI EVERY 2 WEEKS IN KRAS WILD-TYPE METASTATIC COLORECTAL CANCER: PHASE II APEC STUDY. Cheng, Ann-Lii; Cornelio, Gerardo; Shen, Lin; Price, Timothy; Yang, Tsai-Sheng; Chung, Ik-Joo; Dai, Guang-Hai; Lin, Jen-Kou; Sharma, Atul; Yeh, Kun-Huei; Ma, Brigette; Zaatar, Adel; Guan, Zhong-Zhen; Masood, Nehal; Srimuninnimit, Vichien; Yau, Thomas; Sarholz, Barbara; Lim, Robert // Annals of Oncology;Jun2013, Vol. 24 Issue suppl_4, piv34 

    No abstract available.

  • Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial. Madi, A; Fisher, D; Wilson, R H; Adams, R A; Meade, A M; Kenny, S L; Nichols, L L; Seymour, M T; Wasan, H; Kaplan, R; Maughan, T S // British Journal of Cancer;9/25/2012, Vol. 107 Issue 7, p1037 

    Background:COIN compared first-line continuous chemotherapy with the same chemotherapy given intermittently or with cetuximab in advanced colorectal cancer (aCRC).Methods:Choice between oxaliplatin/capecitabine (OxCap) and oxaliplatin/leucovorin (LV)/infusional 5-FU (OxFU) was by physician and...

  • CETUXIMAB AND BEVACIZUMAB EXTEND OVERALL SURVIVAL IN MCRC. Tsvetkova, Elena // Oncology Exchange;Aug2014, Vol. 13 Issue 3, p25 

    The article offers information on the overall survival(OS) rate found in a trial conducted with patients with metastatic colorectal cancer(mCRC). Some patients were assigned cetuximab(cet) or bevacizumab(Bev) every two weeks, or five-FOLFOX chemotherapy in the first line setting. It was found...

  • War on Cancer. Moss, Ralph // Townsend Letter;Jan2014, Issue 366, p34 

    The article reports updates on the state of progress in treating metastatic stage IV colorectal cancer (mCRC) with chemotherapeutic agents as of December 2013. According to the article, the U.S. Food and Drug Administration (FDA) has approved several targeted therapies for mCRC including...

  • KRAS mutations linked to ineffectiveness of cetuximab in colorectal cancer. Eckhardt, S. Gail // Hem/Onc Today;6/25/2008, Vol. 9 Issue 11, p15 

    The article discusses research being done on the link between KRAS mutations and the ineffectiveness of cetuximab in colorectal cancer. It references as study by Eric Van Cutsem and colleagues from the University Hospital Gasthuisberg, Leuven in Belgium. The researchers discovered that the...

  • ERRATUM. PEETERS, MARC; PRICE, TIM; VAN LAETHEM, JEAN-LUC // Oncologist;Mar2009, Vol. 14 Issue 3, p307 

    Two corrections to the article "Anti-Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?," by Marc Peters, Tim Price and Jean-Luc Van Laethem in the 2008 issue are presented including one on the inclusion criteria for the phase III...

  • P-0253XELIRI REGIMEN WITH CONTINUOUS TREATMENT OF BEVACIZUMAB IS WELL-TOLERATED AND EFFECTIVE AS SECOND-LINE CHEMOTHERAPY IN PATIENTS WITH MCRC. Suzuki, Koichi; Kato, Takaharu; Muto, Yuta; Tsujinaka, Shingo; Sasaki, Junichi; Kawamura, Yutaka; Konishi, Fumio; Rikiyama, Toshiki // Annals of Oncology;Jun2013, Vol. 24 Issue suppl_4, piv107 

    No abstract available.

  • Unsupported off-label chemotherapy in metastatic colon cancer. de Souza, Jonas A.; Polite, Blase; Perkins, Monica; Meropol, Neal J.; Ratain, Mark J.; Newcomer, Lee N.; Alexander, G. Caleb // BMC Health Services Research;2012, Vol. 12 Issue 1, p481 

    Background: Newer systemic therapies have the potential to decrease morbidity and mortality from metastatic colorectal cancer, yet such therapies are costly and have side effects. Little is known about their non-evidence-based use. Methods: We conducted a retrospective cohort study using...

  • KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. W. De Roock; H. Piessevaux; J. De Schutter; M. Janssens; G. De Hertogh; N. Personeni; B. Biesmans; J.-L. Van Laethem; M. Peeters; Y. Humblet; E. Van Cutsem; S. Tejpar // Annals of Oncology;Mar2008, Vol. 19 Issue 3, p508 

    Background: KRAS mutation status is a candidate marker for predicting survival in patients with metastatic colorectal cancer (mCRC) treated with cetuximab (CTX). Patients and methods: We studied the KRAS mutation status of 113 patients with irinotecan refractory mCRC treated with CTX in clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics